Drug
Nemtabrutinib
Nemtabrutinib: highest development phase Phase 3, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Nemtabrutinib NCT05947851 | Phase 3 | Leukemia, Lymphocytic, Chronic, B-Cell |
Latest
No recent events.
Follow Nemtabrutinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.